Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
1. GILD released Phase 3 ARTISTRY-1 trial results for BIC/LEN against HIV. 2. The trial demonstrated non-inferiority of BIC/LEN to existing treatments. 3. BIC/LEN showed favorable tolerability with no new safety concerns. 4. Important data from ARTISTRY-2 trial expected before year-end. 5. GILD stock rose 2.97% to $127.07 following the announcement.